Fennec Pharmaceuticals Inc. (FRX.TO)
CAD 7.05
(0.43%)
CAD 7.05
(0.43%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.14 Million | -18.05 Million | -14.22 Million | -15.59 Million | -9.06 Million | -7.82 Million |
| Net Income | -16.04 Million | -23.71 Million | -17.34 Million | -18.1 Million | -12.77 Million | -9.88 Million |
| Depreciation & Amortization | 287 Thousand | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 5.35 Million | 4.22 Million | 4.01 Million | 2.87 Million | 3.08 Million | 1.82 Million |
| Change in working capital | -6.77 Million | 1.1 Million | -932 Thousand | -763 Thousand | 569 Thousand | 132 Thousand |
| Other non-cash items | 326 Thousand | 466 Thousand | 307 Thousand | 486 Thousand | 481 Thousand | 105 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 6.63 Million | 20.73 Million | 4.97 Million | 32.28 Million | -71 Thousand | 2.34 Million |
| Debt repayment | -5 Million | -5 Million | -14 Thousand | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -78 Thousand | -194 Thousand | - | - | - | - |
| Common Stock Issuance | - | - | - | 31.96 Million | - | - |
| Other Financing Activities | -75 Thousand | 25.92 Million | 4.99 Million | 322 Thousand | -71 Thousand | 2.34 Million |
| Accounts receivables | -7.26 Million | -1.54 Million | - | - | - | - |
| Accounts payables | 1.38 Million | 1.61 Million | -794 Thousand | -41 Thousand | 580 Thousand | 177 Thousand |
| Inventory | -1.58 Million | -576 Thousand | - | - | - | - |
| Other working capital | 683 Thousand | 1.61 Million | -138 Thousand | -722 Thousand | -11 Thousand | -45 Thousand |
| Cash at beginning of period | 23.77 Million | 21.1 Million | 30.34 Million | 13.65 Million | 22.78 Million | 28.26 Million |
| Cash at end of period | 13.26 Million | 23.77 Million | 21.1 Million | 30.34 Million | 13.65 Million | 22.78 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -10.5 Million | 2.67 Million | -9.24 Million | 16.69 Million | -9.13 Million | -5.47 Million |
| Free Cash Flow | -17.14 Million | -18.05 Million | -14.22 Million | -15.59 Million | -9.06 Million | -7.82 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -5.55 Million | 12.83 Million | -2.68 Million | -16.04 Million | -1.86 Million | -5.44 Million |
| Depreciation & Amortization | 26 Thousand | 723 Thousand | - | - | - | -52 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 925 Thousand | 1.19 Million | 857 Thousand | 5.35 Million | 865 Thousand | 2.54 Million |
| Change in working capital | -4.21 Million | 23.86 Million | -3.1 Million | -6.77 Million | -1.84 Million | -1.11 Million |
| Other non-cash items | 428 Thousand | 418 Thousand | 66 Thousand | 326 Thousand | 85 Thousand | 73 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 257 Thousand | -1.13 Million | 5.73 Million | 6.63 Million | 201 Thousand | 514 Thousand |
| Debt repayment | - | - | -4.99 Million | -5 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -90 Thousand | -19 Thousand | -17 Thousand | -78 Thousand | -14 Thousand | -27 Thousand |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -90 Thousand | -1.75 Million | -14 Thousand | -75 Thousand | 201 Thousand | 541 Thousand |
| Accounts receivables | -2.03 Million | -1.46 Million | -4.28 Million | -7.26 Million | -2.08 Million | -762 Thousand |
| Accounts payables | -757 Thousand | 1.42 Million | 837 Thousand | 1.38 Million | -64 Thousand | 58 Thousand |
| Inventory | -80 Thousand | 92 Thousand | -401 Thousand | -1.58 Million | -316 Thousand | -521 Thousand |
| Other working capital | -1.33 Million | -1.43 Million | 752 Thousand | 683 Thousand | 617 Thousand | 107 Thousand |
| Cash at beginning of period | 51.18 Million | 13.26 Million | 12.39 Million | 23.77 Million | 14.95 Million | 18.39 Million |
| Cash at end of period | 43.05 Million | 51.18 Million | 13.26 Million | 13.26 Million | 12.39 Million | 14.95 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -8.13 Million | 37.91 Million | 870 Thousand | -10.5 Million | -2.55 Million | -3.43 Million |
| Free Cash Flow | -8.38 Million | 39.04 Million | -4.86 Million | -17.14 Million | -2.76 Million | -3.94 Million |
ADVLIFE
180640
CBIA
FUGI
NINE
KAYNES